...
首页> 外文期刊>Journal of Ovarian Research >Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer
【24h】

Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer

机译:预处理血小板计数和CA125水平(PLT-CA125)分层预后的综合评分(PLT-CA125)FIGO阶段IV上皮卵巢癌患者的分层预后

获取原文
           

摘要

The majority of death-related ovarian cancer is epithelial ovarian cancer (EOC). Regarding the Federation of Gynecology and Obstetrics (FIGO) stage IV EOC, the 5-year overall survival (OS) has not changed in last decades. Platelet (PLT) count and CA125 level are both prognostic markers that related to inflammation and immune evasion in EOC. This study intended to assess the prognostic value of pretreatment PLT count and CA125 level in FIGO stage IV EOC. The study included 108 patients diagnosed with FIGO stage IV EOC and treated with surgery and/or chemotherapy between January 1995 and December 2016. The PLT counts and CA125 levels of the patients before any treatment were analysed with clinical and pathological parameters, OS and progression-free survival (PFS). The survival of different groups was analyzed using the Kaplan-Meier method. The PLT-CA125 scores (0, 1, and 2) were defined basing on the presence of thrombocytosis (PLT count ?400,000/μL), an elevated CA125 level (CA125??1200?U/mL), or both. The prognostic value of PLT-CA125 was assessed with a Cox regression model. Median OS, but not median PFS, was significantly decreased in patients with thrombocytosis or elevated CA125 levels when compared with the others (p?=?0.011 & p?=?0.004). The median OS was significantly decreased in patients with a PLT-CA125 score of 2 [37.8?months; 95% confidence interval (CI) 20.6-54.9] compared with patients with a PLT-CA125 score of 0 (70.0 moths, 95% CI 38.0-101.9, p??0.001). The median PFS was also significantly decreased in patients with a PLT-CA125 score of 2 (19.6?months; 95% CI 13.0-26.3) compared with patients with a PLT-CA125 score of 0 (32.0?months; 95% CI 23.3-40.7, p?=?0.011). Furthermore, multivariate analysis identified both PLT-CA125 scores of 2 and 1 as independent poor prognostic factors for OS (p?=?0.004 & p??0.001) and PFS (p?=?0.033 & p?=?0.017) compared with a PLT-CA125 score of 0. The pretreatment PLT-CA125 score can be a reliable marker with high accessibility for stratifying prognosis in patients with FIGO stage IV EOC.
机译:大多数死亡相关的卵巢癌是上皮卵巢癌(EOC)。关于妇科和产科联合会(FICO)第IV阶段EoC,过去几十年来的5年整体生存(OS)没有改变。血小板(PLT)计数和CA125水平都是与EOC中的炎症和免疫逃避有关的预后标志物。该研究旨在评估Figo阶段IV EoC中预处理PLT数和CA125水平的预后值。该研究包括108名患者,诊断有FIGO阶段IV EOC,并在1995年1月和2016年12月之间用手术和/或化疗治疗。在任何治疗之前,通过临床和病理参数,OS和进展分析了患者的PLT计数和CA125水平 - 自由生存(PFS)。使用Kaplan-Meier方法分析不同组的存活。 PLT-CA125分数(0,1和2)被定义在血小板减少症(PLT计数>α≥400,000/μl)的存在下,升高的Ca125水平(Ca125 ??Δ1200?U / ml),或两者。用COX回归模型评估PLT-CA125的预后值。与其他血小板减少症或CA125水平升高的患者中位OS,但不是中位数PFS(P?= 0.011&P?= 0.004)。 PLT-CA125得分为2 [37.8个月,中位OS​​在患者中显着降低;与PLT-CA125得分为0(70.0蛾,95%CI 38.0-101.9,P≤0.3.01.9,p≤0.9,p≤0.01.9,p≤0.3),95%置信区间(CI)20.6-54.9。与PLT-CA125得分为0(32.0个月的患者,PLT-CA125得分为2(19.6Ω,19.6%; 95%CI 13.0-26.3),中位数PFS也显着降低了2(19.6个月; 95%CI 13.0-26.3)(32.0?月份; 95%CI 23.3- 40.7,p?=?0.011)。此外,多变量分析将PLT-CA125分数均为2和1的分数,作为OS的独立差的预后因子(P?= 0.004&P?<β0.<〜0.033&P?=?0.017)比较PLT-CA125得分为0.预处理PLT-CA125分数可以是具有高可访问性的可靠标记,用于FIGO阶段IV EOC患者分层预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号